Intravenous Tissue Plasminogen Activator for Stroke: A Review of the ECASS III Results in Relation to Prior Clinical Trials

Journal of Emergency Medicine

Volumn 38, Issue 1, 2010, Pages 99-105

  Cronin, Carolyn A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

acute stroke; thrombolysis; tissue plasminogen activator

Indexed keywords

PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BARTHEL INDEX; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; FOOD AND DRUG ADMINISTRATION; GLASGOW OUTCOME SCALE; HUMAN; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; PROGNOSIS; RANKIN SCALE;

EUROPE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 74149095001     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2009.08.004     Document Type: Article

References (28)

1. Reeves M.J., Arora S., Broderick J.P., et al. Acute stroke care in the US: results from 4 pilot prototypes of the paul coverdell national acute stroke registry. Stroke 36 (2005) 1232-1240
2. Kleindorfer D., Lindsell C.J., Brass L., Koroshetz W., and Broderick J.P. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 39 (2008) 924-928
3. Barber P.A., Zhang J., Demchuk A.M., Hill M.D., and Buchan A.M. Why are stroke patients excluded from TPA therapy?. An analysis of patient eligibility. Neurology 56 (2001) 1015-1020
4. California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology 64 (2005) 654-659
5. Hacke W., Kaste M., Bluhmki E., et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359 (2008) 1317-1329
6. Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. the european cooperative acute stroke study (ECASS). JAMA 274 (1995) 1017-1025
7. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
8. Hacke W., Kaste M., Fieschi C., et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352 (1998) 1245-1251
9. Clark W.M., Albers G.W., Madden K.P., and Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic Therapy in Acute Ischemic Stroke Study Investigators. Stroke 31 (2000) 811-816
10. Clark W.M., Wissman S., Albers G.W., Jhamandas J.H., Madden K.P., and Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. the ATLANTIS study: a randomized controlled trial. alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 282 (1999) 2019-2026
11. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
12. Actilyse® website. www.ecass3.com/faq.php Accessed October 30, 2008
13. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke. subgroup analysis of the NINDS t-PA stroke trial. Stroke 28 (1997) 2119-2125
14. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 28 (1997) 2109-2118
15. Saver J.L. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke 38 (2007) 2279-2283
16. Saver J.L. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 61 (2004) 1066-1070
17. Demaerschalk B.M. Thrombolytic therapy for acute ischemic stroke: the likelihood of being helped versus harmed. Stroke 38 (2007) 2215-2216
18. Lansberg M.G., Schrooten M., Bluhmki E., Thijs V.N., and Saver J.L. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin scale. Stroke 40 (2009) 2079-2084
19. Saver J.L., Gornbein J., Grotta J., et al. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial. Stroke 40 (2009) 2433-2437
20. Cunningham V.L. The outcome wheel: a potential tool for shared decision-making in ischemic stroke thrombolysis. CJEM 10 (2008) 545-551
21. Kent D.M., Selker H.P., Ruthazer R., Bluhmki E., and Hacke W. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke 37 (2006) 2957-2962
22. Kent D.M., Selker H.P., Ruthazer R., Bluhmki E., and Hacke W. Can multivariable risk-benefit profiling be used to select treatment-favorable patients for thrombolysis in stroke in the 3- to 6-hour time window?. Stroke 37 (2006) 2963-2969
23. Uyttenboogaart M., Stewart R.E., Vroomen P.C., Luijckx G.J., and De Keyser J. Utility of the stroke-thrombolytic predictive instrument. J Neurol Neurosurg Psychiatry 79 (2008) 1079-1081
24. Wahlgren N., Ahmed N., Davalos A., et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 372 (2008) 1303-1309
25. Lindsay P., Bayley M.M., Hellings C.B., et al. Canadian best practice recommendations for stroke care (updated 2008). CMAJ 179 (2008) S1-S25
26. European Stroke Organization website. www.eso-stroke.org Accessed January 29, 2009
27. Del Zoppo G.J., Saver J.L., Jauch E.C., Adams Jr. H.P., and American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association/American Stroke Association. Stroke 40 (2009) 2945-2948
28. Albers G.W., Bates V.E., Clark W.M., Bell R., Verro P., and Hamilton S.A. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the standard treatment with alteplase to reverse stroke (STARS) study. JAMA 283 (2000) 1145-1150